CAT confirms new CEO
April 08 2002 - 1:02PM
UK Regulatory
RNS Number:2170U
Cambridge Antibody Tech Group PLC
8 April 2002
02/CAT/16
FOR IMMEDIATE RELEASE
Monday 8 April 2002
For Further Information Contact:
Cambridge Antibody Technology Weber Shandwick Square Mile (Europe)
Tel: +44 (0) 1763 263 233 Tel: +44 (0) 20 7950 2800
John Aston, Finance Director Kevin Smith
Rowena Gardner, Head of Corporate Graham Herring
Communications
BMC Communications/The Trout Group (USA)
Tel: 001 212 477 9007
Brad Miles, ext 17 (media)
Brandon Lewis, ext.15 (investors)
CAMBRIDGE ANTIBODY TECHNOLOGY CONFIRMS
APPOINTMENT OF NEW CHIEF EXECUTIVE OFFICER
Melbourn, UK... Cambridge Antibody Technology (LSE: CAT; NASDAQ: CATG) is
pleased to confirm that Mr Peter Chambre was formally appointed as a director
and Chief Executive Officer of the Company with effect from the commencement of
business today.
In respect of the appointment of a new director, Rule 16.4 of Listing Rules
requires disclosure of all directorships held in any other publicly quoted
companies at any time in the past five years. Mr Chambre is not currently a
director of any other publicly quoted company either in the UK or elsewhere. He
was a director of Bespak plc from 9 March 1994 to 29 July 2000.
None of the other disclosure requirements relating to Rule 16.4 of the Listing
Rules are relevant to Mr Chambre.
Neither Mr Chambre nor his immediate family nor any connected person hold any
securities that are, or are to be, listed in the Company pursuant to section 324
and 328 of the Companies Act 1985 or entered in the Company's register in
accordance with section 325 (3) or (4) of that Act and accordingly no further
disclosure requirement arises pursuant to Rule 16.13 of the Listing Rules.
-ENDS-
Cambridge Antibody Technology (CAT)
• CAT is a UK biotechnology company using its proprietary technologies in
human monoclonal antibodies for drug discovery and drug development. Based
near Cambridge, England, CAT currently employs around 270 people.
• CAT is listed on the London Stock Exchange and has been listed on NASDAQ
since June 2001. CAT raised £41m in its IPO in March 1997 and £93m in a
secondary offering in April 2000.
• CAT has an advanced platform technology for rapidly isolating human
monoclonal antibodies using phage display systems. CAT has extensive phage
antibody libraries, currently incorporating more than
• 100 billion distinct antibodies. These libraries form the basis for the
Company's strategy to develop a portfolio of antibody-based drugs and to
utilise antibodies as tools for target validation. Six human therapeutic
antibodies developed by CAT are at various stages of clinical trials.
• CAT has alliances with a large number of biotechnology and pharmaceutical
companies to discover, develop and commercialise human monoclonal
antibody-based products. CAT has also licensed its proprietary human
antibody phage display libraries to several companies for target validation
and drug discovery. CAT's collaborators include: Abbott, AMRAD, Elan, Eli
Lilly, Genetics Institute, Genzyme, Human Genome Sciences, Immunex, Incyte,
Merck & Co., Inc, Oxford GlycoSciences, Pharmacia, Pfizer, Wyeth-Ayerst,
Xerion and Zyomyx.
Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934.
These forward looking statements are based on numerous assumptions regarding
CAT's present and future business strategies and the environment in which CAT
will operate in the future. Certain factors that could cause CAT's actual
results, performance or achievements to differ materially from those in the
forward looking statements include: market conditions, CAT's ability to enter
into and maintain collaborative arrangements, success of product candidates in
clinical trials, regulatory developments and competition.
This information is provided by RNS
The company news service from the London Stock Exchange
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Jul 2024 to Aug 2024
Catco Reinsurance Opport... (LSE:CAT)
Historical Stock Chart
From Aug 2023 to Aug 2024